Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control

INTRODUCTION: The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Ther
Autors principals: Tentolouris, Nikolaos, Knudsen, Søren T., Lapolla, Annunziata, Wolden, Michael Lyng, Haldrup, Steffen, Schultes, Bernd
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824376/
https://ncbi.nlm.nih.gov/pubmed/30879256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00916-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars